LFVN — LifeVantage Corporation

LifeVantage Corporation (LFVN) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: $48.9 million, down 27.8% year-over-year from $67.8 million in Q2 2025, but up 2.9% sequentially from Q1 2026.
• MINDBODY GLP-1 System Sales: Decreased by $16.2 million compared to the prior year, significantly impacting overall revenue.
• LoveBiome Contribution: Generated $4.1 million in revenue post-acquisition.
• Gross Profit Margin: 74%, down from 80.5% in the prior year, impacted by a one-time inventory reserve of $2.4 million.
• Operating Income: GAAP operating income of $500,000 compared to $3.4 million in Q2 2025; adjusted non-GAAP operating income was $2.6 million, down from $3.9 million.
• Net Income: GAAP net income of $300,000 ($0.02 per share) compared to $2.6 million ($0.19 per share) in the prior year.
• Adjusted EBITDA: $3.9 million (7.9% of revenue), down from $6.5 million (9.6% of revenue) in Q2 2025.
• Cash Position: $10.2 million with no debt; cash from operations was $500,000 for the first half of 2026.

2. Strategic Updates and Business Highlights:

• LoveBiome Integration: Successfully integrated LoveBiome, launching two new products (Axila X and Phytopower B) that are expected to enhance product offerings and consultant engagement.
• Shopify Partnership: Progressing on a partnership with Shopify to modernize e-commerce capabilities, aiming to improve customer experience and conversion rates.
• Product Development: Continued innovation in the wellness ecosystem, focusing on cellular health, metabolic wellness, and gut health.
• Shareholder Returns: Announced a new $60 million share repurchase program and a quarterly dividend of $0.45 per share.

3. Forward Guidance and Outlook:

• Revenue Guidance: Expected to range between $185 million to $200 million for fiscal 2026.
• Adjusted EBITDA Guidance: Projected between $15 million to $19 million.
• Adjusted EPS Guidance: Anticipated between $0.60 to $0.80 per fully diluted share.

4. Bad News, Challenges, or Points of Concern:

• Competitive Pressures: Increased competition in the GLP-1 market, with pharmaceutical alternatives becoming more accessible and affordable, impacting MINDBODY sales.
• Declining Active Accounts: Total active accounts decreased by 25.2%, contributing to revenue decline.
• Inventory Reserve: Recognized a reserve against GLP-1 inventory due to overestimation of demand, reflecting a conservative approach to current market conditions.
• Overall Revenue Decline: Q2 revenue fell below $50 million for the first time in several years, raising concerns about the sustainability of growth.

5. Notable Q&A Insights:

• MINDBODY Marketing Strategy: Implemented a multi-pronged marketing strategy, including discounts and a win-back campaign to re-engage past customers.
• LoveBiome Financial Impact: Clarified that the $3.7 million cash outflow was the purchase price for LoveBiome, with potential future earn-out based on revenue targets.
• Shopify Impact: Emphasized that the Shopify partnership aims to enhance e-commerce efficiency and consultant tools, positioning LifeVantage for future growth.
• Management Transition: CEO Steve Fife announced his planned retirement in April, with a succession plan in place to ensure continuity.

Overall, while LifeVantage faces significant challenges in the competitive landscape, particularly with its MINDBODY product, the company is taking strategic steps to stabilize and grow its business through product innovation, effective integration of acquisitions, and modernization of its technology infrastructure.